Jing Yang

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression

Eric D. Jacobsen, Jeff P. Sharman, Yasuhiro Oki et al. · Blood · 2015 · 297 citations · Full text

Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry

Nancy L. Bartlett, Mitchell R. Smith, Tanya Siddiqi et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2016 · 59 citations

The risk variant rs884225 within EGFR impairs miR-103a-3p’s anti-tumourigenic function in non-small cell lung cancer

Zhongyi Fan, Jing Yang, Dong Zhang et al. · Oncogene · 2018 · 27 citations

Anti-tumourigenic Function, Risk Variant Rs884225, Medicine +10

Half-curcumin analogues as PET imaging probes for amyloid beta species

Jian Yang, Ran Cheng, Hualong Fu et al. · Chemical Communications · 2019 · 24 citations

Better Scaffold, Neurochemical Biomarkers, Fluorescent Spectral Tests +17

Light-controlled fluorescent probes for precisely monitoring brain amyloid-β aggregates in Alzheimer's disease

Yinhui Gu, Zhonglong Ding, Cheng Zheng et al. · Chemical Engineering Journal · 2022 · 24 citations

Neurodegenerative Diseases, Alzheimer's Disease, Engineering +13